Cargando…

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal breast cancer patients. Age oestrogen (ER) and progesterone (PR) receptor status are accurately considered to select patients for hormonal treatment. However, additional markers are needed. By immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soubeyran, I., Quénel, N., Coindre, J. M., Bonichon, F., Durand, M., Wafflart, J., Mauriac, L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077113/ https://www.ncbi.nlm.nih.gov/pubmed/8855985

Ejemplares similares

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.
por: Soubeyran, I., et al.
Publicado: (1996)

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
por: MacGrogan, G., et al.
Publicado: (1996)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer.
por: Fentiman, I. S., et al.
Publicado: (1994)

Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance.
por: Trojani, M., et al.
Publicado: (1987)

Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up.
por: de Mascarel, I., et al.
Publicado: (1992)

Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance.
por: Trojani, M., et al.
Publicado: (1987)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
por: Foekens, J. A., et al.
Publicado: (1994)

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
por: PyrhÃ¶nen, S., et al.
Publicado: (1997)

The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo.
por: Powles, T. J., et al.
Publicado: (1998)

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis
por: Debled, M, et al.
Publicado: (2007)

Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers
por: O'Neill, P A, et al.
Publicado: (2004)

Factors related to the experience of menopausal symptoms in women prescribed tamoxifen
por: Moon, Zoe, et al.
Publicado: (2017)

Epithelial atypia in biopsies performed for microcalcifications. Practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-up
por: de Mascarel, Isabelle, et al.
Publicado: (2007)

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas
por: Soubeyran, P, et al.
Publicado: (1999)

Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
por: Busch, Susann, et al.
Publicado: (2012)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer
por: MacGrogan, G, et al.
Publicado: (2003)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1989)

Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer
por: Pujol, P, et al.
Publicado: (1999)

Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
por: Baneshi, M R, et al.
Publicado: (2010)

An examination of obesity and breast cancer survival in post-menopausal women.
por: Katoh, A., et al.
Publicado: (1994)

Imaging in breast cancer: Diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy
por: Tromberg, Bruce J, et al.
Publicado: (2005)

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
por: Bontenbal, M., et al.
Publicado: (1998)

Regarding the Use of Tamoxifen Post-Oophorectomy to Prevent Hereditary Breast Cancer
por: Narod, Steven A
Publicado: (2006)

Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment
por: Ramalingam, Kirithiga, et al.
Publicado: (2023)

Correlates of Biochemical Markers of Bone turnover among Post-Menopausal Women
por: Khadka, Bikram, et al.
Publicado: (2018)

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer
por: Isnaldi, Edoardo, et al.
Publicado: (2022)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001)

Vaginal pH: A marker for menopause
por: Panda, Subrat, et al.
Publicado: (2014)

Cohort Study of Risk Factors for Breast Cancer in Post Menopausal Women
por: Hartz, Arthur J., et al.
Publicado: (2013)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
por: Chamnanphon, Montri, et al.
Publicado: (2013)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Body weight and vascular invasion in post-menopausal women with breast cancer.
por: Badwe, R. A., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_v6b8qsrqj7dd0eni4d3g6dm8k5